Contents

Foreword xi

Preface to the Sixth Edition xiii

List of Contributors xv

Acknowledgements xvii

1 Adverse Drug Reactions: History, Terminology, Classification, Causality, Frequency, Preventability 1
   Jeffrey K. Aronson
   1.1 Introduction 1
   1.2 Defining pharmacovigilance 1
   1.3 The modern history of pharmacovigilance 3
   1.4 Terminology and definitions in pharmacovigilance 6
   1.5 Medication errors 25
   1.6 Pharmacological classification of adverse drug reactions 32
   1.7 Drug interactions 53
   1.8 Reporting suspected adverse drug reactions 59
   1.9 Causality assessment 64
   1.10 Frequencies of adverse drug reactions 69
   1.11 Risk perception and adverse drug reactions 77
   1.12 Class effects of drugs 78
   1.13 Unlicensed indications, off-label uses, and orphan drugs 80
   1.14 Preventing adverse drug reactions 84
   1.15 Publishing accounts of adverse drug reactions 95
   References 101

2 Pharmacogenetics of Adverse Drug Reactions 121
   Sudeep P. Pushpakom and Munir Pirmohamed
   2.1 Introduction 121
   2.2 Historical review 121
## CONTENTS

2.3 Sources of genetic variability  
2.4 Role of pharmacogenetic factors in drug pharmacokinetics  
2.5 Role of pharmacogenetic factors in drug pharmacodynamics  
2.6 The role of pharmacogenetics in pharmaceutical companies  
2.7 The impact of pharmacogenetics on regulatory agencies  
2.8 The impact of pharmacogenetics on clinical practice  
2.9 Conclusions  
References  
122  
123  
133  
139  
141  
143  
145  
145

### 3 Toxicology and Adverse Drug Reactions  
D. J. Snodin and A. Suitters  

3.1 Introduction  
3.2 Toxicity testing  
3.3 Drug discovery and development  
3.4 Data interpretation and risk assessment  
3.5 Adverse drug reactions detected after marketing authorization  
3.6 Examples of toxicological investigation of ADRs  
3.7 Conclusions  
References  
157  
157  
168  
174  
186  
199  
200  
201  
201

### 4 Clinical Trials—Collecting Safety Data and Establishing the Adverse Drug Reactions Profile  
John Talbot, Marianne Keisu, and Lars Ståhle  

4.1 Introduction  
4.2 Adverse events  
4.3 Clinical studies and safety  
4.4 The emerging safety profile  
4.5 Presentation of safety data  
4.6 Conclusions  
References  
215  
216  
236  
267  
271  
280  
281

### 5 Clinical Laboratory Safety Data  
Alan Craig  

5.1 Introduction  
5.2 Factors that influence the interpretation of clinical laboratory data  
5.3 Sample collection procedure  
5.4 Analytical variation  
5.5 Reference ranges  
5.6 Intra-individual biological variation  
5.7 Detecting adverse events during drug development  
5.8 Test selection  
5.9 Exclusion criteria and “panic levels”  
5.10 Harmonization of data from different laboratories  
5.11 Data analysis and presentation  
5.12 Conclusions  
5.13 Appendix  
References  
291  
294  
300  
301  
304  
307  
309  
333  
335  
337  
339  
344  
345  
346
CONTENTS

6 Statistics: Analysis and Presentation of Safety Data 349
Stephen J. W. Evans and Dorothea Nitsch
6.1 Introduction and background 349
6.2 Problems with efficacy trials for detecting adverse drug reactions 352
6.3 Analysis and presentation of data from trials 355
6.4 Statistical measures of the occurrence of adverse events 356
6.5 Combining data from several trials—meta-analysis 364
6.6 Use of statistical methods for signal detection from spontaneous reports 365
6.7 Analysis and presentation of data from observational studies 373
6.8 Summary and conclusions 384
Acknowledgements 385
References 386

7 Proactive Pharmacovigilance and Risk Management 389
June Raine, Lesley Wise, John Talbot, and Jeffrey K. Aronson
7.1 Introduction 389
7.2 Risk management—definition and general principles 390
7.3 Defining the knowledge base—the safety specification 391
7.4 Extending the knowledge of safety and characterizing risk—the pharmacovigilance plan 394
7.5 Minimizing risks 395
7.6 Special challenges for risk management 397
7.7 Experience with risk evaluation and mitigation strategies (REMS) in the USA 398
7.8 A possible method for risk management when a new adverse reaction is discovered after marketing 399
7.9 Future challenges for risk management 405
7.10 Conclusions 406
References 407

8 Regulatory Aspects of Pharmacovigilance 411
Kristina Leila Strutt and Barry David Charles Arnold
8.1 Introduction 411
8.2 The standardization and harmonization of safety data collection and reporting: CIOMS and ICH 412
8.3 The European Union 447
8.4 The UK 481
8.5 France 483
8.6 Germany 485
8.7 USA 487
8.8 Japan
  Acknowledgements 505
  References 506
  Useful web sites 509

9 Legal Aspects of Pharmacovigilance in the European Union 511
Christine H. Bendall
9.1 Introduction 511
9.2 Application of EU legislation in Member States 511
9.3 Interpretation of EU law 514
9.4 Relationship between law and guidelines 515
## CONTENTS

9.5 Issues in interpreting EU pharmacovigilance legislation 517
9.6 Legal responsibility for pharmacovigilance activities 519
9.7 Failures to meet pharmacovigilance requirements 522
9.8 Enforcement and sanctions 524
9.9 European powers and procedures in the event of a product safety issue 528
9.10 Civil liability 534
9.11 Personal data privacy 537
9.12 Safety in research products 538
References 541

10 Dictionaries and Coding in Pharmacovigilance 545
E. G. Brown and J. E. Harrison
10.1 Introduction 545
10.2 Scope of this chapter 546
10.3 What is a dictionary? 546
10.4 Drug dictionaries 547
10.5 Disease classifications 554
10.6 Medical Dictionary for Regulatory Activities, MedDRA® 557
10.7 Common Terminology Criteria for Adverse Events (CTCAE) 567
10.8 Definition of adverse reaction terms 567
10.9 Dictionaries used in electronic health records 568
10.10 Use of dictionaries in standard product information 570
10.11 Conclusions 571
Acknowledgements 571
References 571

11 Adverse Drug Reactions: Societal Considerations 573
Nicky Britten
11.1 Introduction 573
11.2 Adverse drug reactions at the population level 574
11.3 The social production of ADRs 576
11.4 Trust 579
11.5 Information about ADRs 581
11.6 Conclusions 583
References 583

12 Safety of Biotherapeutics 585
Andrew Erdman, James Nickas, and Benton Brown
12.1 Introduction 585
12.2 Properties of proteins 586
12.3 Classification of biotherapeutics 587
12.4 Monitoring for adverse events due to biotherapeutics 589
12.5 Conclusions 598
References 598

13 Vaccine Safety Surveillance 603
E. Miller and J. Stowe
13.1 Introduction 603
13.2 What is special about vaccine safety compared with other drugs? 604
# CONTENTS

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.3</td>
<td>Pathogenesis of vaccine reactions</td>
<td>605</td>
</tr>
<tr>
<td>13.4</td>
<td>Criteria for establishing causality after vaccine-related adverse events</td>
<td>608</td>
</tr>
<tr>
<td>13.5</td>
<td>Pre-licensing evaluation of vaccine safety</td>
<td>610</td>
</tr>
<tr>
<td>13.6</td>
<td>Objectives of an ideal post-licensing vaccine safety surveillance system</td>
<td>611</td>
</tr>
<tr>
<td>13.7</td>
<td>Conclusions</td>
<td>620</td>
</tr>
<tr>
<td>14</td>
<td>Assessing the Safety of Drugs Used in Oncology</td>
<td>625</td>
</tr>
<tr>
<td></td>
<td>Anne Kehely</td>
<td></td>
</tr>
<tr>
<td>14.1</td>
<td>Introduction</td>
<td>625</td>
</tr>
<tr>
<td>14.2</td>
<td>Factors to consider when assessing the safety of drugs used in oncology</td>
<td>627</td>
</tr>
<tr>
<td>14.3</td>
<td>Sources of adverse effect data</td>
<td>632</td>
</tr>
<tr>
<td>14.4</td>
<td>Nature of the data</td>
<td>634</td>
</tr>
<tr>
<td>14.5</td>
<td>Assessment of adverse effects data in oncology</td>
<td>635</td>
</tr>
<tr>
<td>14.6</td>
<td>Conclusions</td>
<td>641</td>
</tr>
<tr>
<td></td>
<td>References</td>
<td>642</td>
</tr>
<tr>
<td>15</td>
<td>Adverse Drug Reactions and Pharmacovigilance of Herbal Medicines</td>
<td>645</td>
</tr>
<tr>
<td></td>
<td>Joanne Barnes</td>
<td></td>
</tr>
<tr>
<td>15.1</td>
<td>Introduction</td>
<td>645</td>
</tr>
<tr>
<td>15.2</td>
<td>Herbal medicines: definitions and descriptions</td>
<td>646</td>
</tr>
<tr>
<td>15.3</td>
<td>Characteristics of herbal medicines</td>
<td>647</td>
</tr>
<tr>
<td>15.4</td>
<td>Regulation of herbal medicines and pharmacovigilance requirements</td>
<td>648</td>
</tr>
<tr>
<td>15.5</td>
<td>Access to and use of herbal medicines</td>
<td>655</td>
</tr>
<tr>
<td>15.6</td>
<td>Adverse reactions associated with herbal medicines</td>
<td>656</td>
</tr>
<tr>
<td>15.7</td>
<td>Methods for pharmacovigilance of herbal medicines</td>
<td>666</td>
</tr>
<tr>
<td>15.8</td>
<td>Responding to safety concerns associated with herbal medicines</td>
<td>673</td>
</tr>
<tr>
<td>15.9</td>
<td>The future for pharmacovigilance of herbal medicines</td>
<td>674</td>
</tr>
<tr>
<td>15.10</td>
<td>Conclusions</td>
<td>675</td>
</tr>
<tr>
<td></td>
<td>References</td>
<td>676</td>
</tr>
<tr>
<td>A1.1</td>
<td>Introduction</td>
<td>685</td>
</tr>
<tr>
<td>A1.2</td>
<td>Ten national pharmacovigilance web sites</td>
<td>685</td>
</tr>
<tr>
<td>A1.3</td>
<td>Twelve institutional web sites</td>
<td>689</td>
</tr>
<tr>
<td></td>
<td>Acknowledgements</td>
<td>697</td>
</tr>
<tr>
<td></td>
<td>References</td>
<td>697</td>
</tr>
<tr>
<td>A2.1</td>
<td>Introduction</td>
<td>699</td>
</tr>
<tr>
<td>A2.2</td>
<td>Notes on the checklist</td>
<td>700</td>
</tr>
<tr>
<td>A2.3</td>
<td>Conclusions</td>
<td>706</td>
</tr>
<tr>
<td></td>
<td>Note</td>
<td>706</td>
</tr>
<tr>
<td></td>
<td>References</td>
<td>706</td>
</tr>
</tbody>
</table>

### Appendix 1 Web Sites Relevant to Pharmacovigilance—An Analysis of Contents

<table>
<thead>
<tr>
<th>Subsection</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>A1.1</td>
<td>Introduction</td>
<td>685</td>
</tr>
<tr>
<td>A1.2</td>
<td>Ten national pharmacovigilance web sites</td>
<td>685</td>
</tr>
<tr>
<td>A1.3</td>
<td>Twelve institutional web sites</td>
<td>689</td>
</tr>
<tr>
<td>A1.3.1</td>
<td>Acknowledgements</td>
<td>697</td>
</tr>
<tr>
<td>A1.3.2</td>
<td>References</td>
<td>697</td>
</tr>
</tbody>
</table>

### Appendix 2 Guidelines and a Checklist for Reporting Suspected Adverse Drug Reactions Anecdotally in Journals

<table>
<thead>
<tr>
<th>Subsection</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>A2.1</td>
<td>Introduction</td>
<td>699</td>
</tr>
<tr>
<td>A2.2</td>
<td>Notes on the checklist</td>
<td>700</td>
</tr>
<tr>
<td>A2.3</td>
<td>Conclusions</td>
<td>706</td>
</tr>
<tr>
<td>A2.3.1</td>
<td>Note</td>
<td>706</td>
</tr>
<tr>
<td>A2.3.2</td>
<td>References</td>
<td>706</td>
</tr>
</tbody>
</table>

### Index

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>J</td>
<td>709</td>
</tr>
</tbody>
</table>